JAK2V617F mutation in patients with splanchnic vein thrombosis

Digestive Diseases and Sciences

Volumn 55, Issue 6, 2010, Pages 1770-1777

  Xavier, Sandra Guerra ^a,b,e   Gadelha, Telma ^a,f   Pimenta, Glicínia ^a,f   Eugenio, Angela Maria ^a,f   Ribeiro, Daniel Dias ^b   Gomes, Fernanda Mendes ^c,e   Bonamino, Martin ^c,e   Zalcberg, Ilana Renault ^c,e   Spector, Nelson ^a,d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^d Instituto Nacional de Câncer ^*  (Brazil)

^e Cidade Universitária ^*  (Brazil)

^f Hospital Universitário   (Brazil)

Author keywords

Allele burden; Budd Chiari syndrome; JAK2; Liver cirrhosis; Myeloproliferative neoplasms; Portal vein thrombosis

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; VALINE;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CANCER; BUDD CHIARI SYNDROME; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE MUTATION; HEMOSTASIS; HETEROZYGOTE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SPLANCHNIC VEIN THROMBOSIS; VEIN THROMBOSIS;

EID: 77954425724     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0933-y     Document Type: Article

References (46)

1. R Marchioli G Finazzi R Landolfi, et al. 2005 Vascular and neoplastic risk in a large cohort of patients with polycythemia vera J Clin Oncol 23 2224 2232 10.1200/JCO.2005.07.062 15710945 (Pubitemid 46218714)
2. BR Anger E Seifried J Scheppach H Heimpel 1989 Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases Klin Wochenschr 67 818 825 10.1007/BF01725198 1:STN:280:DyaK3c%2FhtlWnsA%3D%3D 2796252 (Pubitemid 19203178)
3. M Bazzan G Tamponi P Schinco, et al. 1999 Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia Ann Hematol 78 539 543 10.1007/s002770050555 1:STN:280:DC%2BD3c7ht1CjsQ%3D%3D 10647877 (Pubitemid 30009355)
4. MH Denninger Y Chaït N Casadevall, et al. 2000 Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors Hepatology 31 587 591 10.1002/hep.510310307 1:STN:280:DC%2BD3c7nt1Sjug%3D%3D 10706547 (Pubitemid 30118625)
5. HLA Janssen JR Meinardi FP Vleggaar, et al. 2000 Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study Blood 96 2364 2368 1:CAS:528:DC%2BD3cXntVarur4%3D 11001884
6. D Valla 2002 Hepatic vein thrombosis (Budd-Chiari Syndrome) Semin Liver Dis 22 5 14 10.1055/s-2002-23202 11928075 (Pubitemid 34225968)
7. M Primignani I Martinelli P Bucciarelli, et al. 2005 Risk factors for thrombophilia in extrahepatic portal vein obstruction Hepatology 41 603 608 10.1002/hep.20591 1:CAS:528:DC%2BD2MXisFCrs7o%3D 15726653 (Pubitemid 40289509)
8. Y Chait B Condat D Cazals-Hatem, et al. 2005 Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis Br J Haematol 129 553 560 10.1111/j.1365-2141.2005. 05490.x 15877740 (Pubitemid 40769907)
9. JL Spivak 2002 Polycythemia vera: myths, mechanisms, and management Blood 100 4272 4290 10.1182/blood-2001-12-0349 1:CAS:528:DC%2BD38XpsFCqsrY%3D 12393615 (Pubitemid 35429665)
10. PJ Thurmes DP Steensma 2006 Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis Eur J Haematol 77 57 60 10.1111/j.1600-0609.2006.00667.x 1:CAS:528:DC%2BD28XnslSrur0%3D 16827884 (Pubitemid 43876206)
11. EJ Baxter LM Scott PJ Campbell, et al. 2005 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054 1061 1:CAS:528:DC%2BD2MXisFGrs7g%3D 15781101 (Pubitemid 40386783)
12. C James V Ugo J-P Le-Couédic, et al. 2005 A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144 1148 10.1038/nature03546 1:CAS:528:DC%2BD2MXjsF2ltbk%3D 15793561 (Pubitemid 40663494)
13. RL Levine M Wadleigh J Cools, et al. 2005 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia Cancer Cell 7 387 397 10.1016/j.ccr.2005.03.023 1:CAS:528:DC%2BD2MXjvFSku7o%3D 15837627 (Pubitemid 40544655)
14. R Kralovics F Passamonti AS Buser, et al. 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 1779 1790 10.1056/NEJMoa051113 1:CAS:528:DC%2BD2MXjsFyhsLw%3D 15858187 (Pubitemid 40570926)
15. AI Schafer 2006 Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia Blood 107 4214 4222 10.1182/blood-2005-08-3526 1:CAS:528:DC%2BD28Xlt1Cgsrc%3D 16484586 (Pubitemid 43801343)
16. CA Smith G Fan 2008 The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms Hum Pathol 39 795 810 10.1016/j.humpath.2008.02.004 1:CAS:528:DC%2BD1cXmvFemurw%3D 18538168 (Pubitemid 351758946)
17. V De Stefano A Fiorini E Rossi, et al. 2007 Incidence of the JAK2V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders J Thromb Haemost 5 708 714 10.1111/j.1538-7836.2007.02424.x 17263783 (Pubitemid 46563568)
18. RK Patel NC Lea MA Heneghan, et al. 2006 Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome Gastroenterology 130 2031 2038 10.1053/j.gastro.2006.04.008 1:CAS:528:DC%2BD28XntVWitr4%3D 16762626 (Pubitemid 43816970)
19. M Primignani G Barosi G Bergamaschi, et al. 2006 Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis Hepatology 44 1528 1534 10.1002/hep.21435 1:CAS:528: DC%2BD2sXislKktg%3D%3D 17133457 (Pubitemid 44953658)
20. V617F tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis Int J Lab Haematol 30 415 419 10.1111/j.1751-553X.2007.00973.x 1:STN:280: DC%2BD1cjnvVKqtw%3D%3D
21. S Regina O Herault L D'Alteroche C Binet Y Gruel 2007 JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis J Thromb Haemost 5 859 861 10.1111/j.1538-7836.2007.02384.x 1:CAS:528: DC%2BD2sXltlWgtb4%3D 17403204 (Pubitemid 46563588)
22. AF Remacha C Estivill MP Sarda, et al. 2007 The V617F mutation of JAK2 is very uncommon in patients with thrombosis Haematologica 92 285 286 10.3324/haematol.10358 17296594 (Pubitemid 46852446)
23. A Pardanani TL Lasho WG Morice RK Pruthi A Tefferi 2007 JAK2V617F is infrequently associated with arterial stroke in the absence of overt myeloproliferative disorder J Thromb Haemost 5 1784 1785 10.1111/j.1538-7836. 2007.02616.x 1:CAS:528:DC%2BD2sXhtVent7rL 17488346 (Pubitemid 47091425)
24. D Colaizzo L Amitrano L Iannaccone, et al. 2007 Gain-of-function gene mutations and venous thromboembolism: distinct roles in different clinical settings J Med Genet 44 412 416 10.1136/jmg.2006.048371 1:CAS:528: DC%2BD2sXnvFOitrs%3D 17307838 (Pubitemid 46953726)
25. A Pardanani TL Lasho K Hussein, et al. 2008 JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients Mayo Clin Proc 83 457 459 10.4065/83.4.457 18380991 (Pubitemid 351536475)
26. SG Xavier T Gadelha R Schaffel, et al. 2008 Low prevalence of the JAK2V617F in patients with ischemic stroke or cerebral venous thrombosis Blood Coagul Fibrinolysis 19 468 469 10.1097/MBC.0b013e328304e0a9 1:CAS:528: DC%2BD1cXotFCjsrY%3D 18600104
27. Pierre R, Imbert M, Thiele J, et al. WHO classification of the chronic myeloproliferative diseases (CMPD) polycythemia vera, chronic idiopathic myelofibrosis, essential thrombocythemia and CMPD unclassifiable. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours, vol. 3. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:32-44.
28. A Tefferi J Thiele A Orazi, et al. 2007 Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood 110 1092 1097 10.1182/blood-2007-04- 083501 1:CAS:528:DC%2BD2sXptFKmurg%3D 17488875 (Pubitemid 47281402)
29. CR Newton A Graham LE Heptinstall, et al. 1989 Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS) Nucleic Acids Res 17 2503 2516 10.1093/nar/17.7.2503 1:CAS:528:DyaL1MXktFyktbs%3D 2785681 (Pubitemid 19103235)
30. Bonamino M, Gomes F, Guimarães-Sternberg C, et al. Qualitative and Quantitative Analysis of JAK2V617F Mutations Unravels Higher Responsiveness of JAK2 + ET Patients Treated with Hydroxyurea. 14th Congress of the EHA, 2009, abstract 1790 (ahead of print).
31. AV Jones S Kreil K Zoi, et al. 2005 Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders Blood 106 2162 2168 10.1182/blood-2005-03-1320 1:CAS:528:DC%2BD2MXhtVWksLvF 15920007 (Pubitemid 41291734)
32. FR Rosendaal 1999 Venous thrombosis: a multicausal disease Lancet 353 1167 1173 10.1016/S0140-6736(98)10266-0 1:CAS:528:DyaK1MXisFGlsrg%3D 10209995 (Pubitemid 29155221)
33. M Primignani PM Mannucci 2008 The role of thrombophilia in splanchnic vein thrombosis Semin Liver Dis 28 293 301 10.1055/s-0028-1085097 18814082
34. V De Stefano L Teofili G Leone JJ Michiels 1997 Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis Semin Thromb Hemost 23 411 418 10.1055/s-2007-996117 9387199 (Pubitemid 27501780)
35. FL Fimognari F Violi 2008 Portal vein thrombosis in liver cirrhosis Intern Emerg Med 3 213 218 10.1007/s11739-008-0128-0 18274708
36. D Colaizzo L Amitrano GL Tiscia, et al. 2007 The JAK2V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis J Thromb Haemost 5 55 61 10.1111/j.1538-7836.2006.02277.x 1:CAS:528: DC%2BD2sXhsFyitbo%3D 17059429 (Pubitemid 46958816)
37. JJ Kiladjian F Cervantes FWG Leebeek, et al. 2008 The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases Blood 11 4922 4929 10.1182/blood-2007-11-125328
38. Y Bayraktar O Harmanci Y Büyükasik, et al. 2008 JAK2V617F mutation in patients with portal vein thrombosis Dig Dis Sci 53 2778 2783 10.1007/s10620-008-0225-y 1:CAS:528:DC%2BD1cXhtVGnsbnN 18343999
39. R Landolfi L Di Gennaro A Falanga 2008 Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation Leukemia 22 2020 2028 10.1038/leu.2008.253 1:CAS:528:DC%2BD1cXhtlGrtbfF 18800144
40. S Sozer MI Fiel T Schiano M Xu J Mascarenhas R Hoffman 2009 The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome Blood 113 5246 5249 10.1182/blood-2008-11-191544 1:CAS:528:DC%2BD1MXmslalu70%3D 19293426
41. PJ Campbell AR Green 2006 The myeloproliferative disorders N Engl J Med 355 2452 2466 10.1056/NEJMra063728 1:CAS:528:DC%2BD28Xht12nt7vN 17151367 (Pubitemid 44903749)
42. G Barosi G Bergamaschi M Marchetti, et al. 2007 JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis Blood 110 4030 4036 10.1182/blood-2007-07-099184 1:CAS:528:DC%2BD2sXhtl2qsb%2FK 17712047 (Pubitemid 350248459)
43. AM Vannucchi E Antonioli P Guglielmelli A Pardanani A Tefferi 2008 Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal Leukemia 22 1299 1307 10.1038/leu.2008.113 1:CAS:528:DC%2BD1cXosFSmsr8%3D 18496562
44. C McMahon K Abu-Elmagd FA Bontempo JA Kant SH Swerdlow 2007 JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses Am J Clin Pathol 127 736 743 10.1309/JA1WD8JNVLGYNQYE 1:CAS:528:DC%2BD2sXmtlSltrg%3D 17439832
45. V De Stefano A Fiorini E Rossi, et al. 2007 High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis Hepatology 45 831 832 10.1002/hep.21601 17326212 (Pubitemid 46450639)
46. M Boissinot E Lippert F Girodon, et al. 2006 Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis Blood 108 3223 3224 10.1182/blood-2006-05-021527 1:CAS:528:DC%2BD28XhtFygtrfN 17057021